ORIGINAL RESEARCH article
Front. Cell Dev. Biol.
Sec. Cell Adhesion and Migration
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1532656
This article is part of the Research TopicRegulation of Permeability of Tight JunctionsView all 3 articles
Azithromycin mitigates human rhinovirus impact on barrier integrity and function in non-diseased airway epithelium
Provisionally accepted- 1Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Perth, Australia
- 2Curtin School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Australia
- 3Centre for Child Health Research, Telethon Kids Institute, University of Western Australia, Crawley, Western Australia, Australia
- 4Centre for Cell Therapy and Regenerative Medicine, School of Medicine, University of Western Australia, Perth, Western Australia, Australia
- 5Department of Respiratory and Sleep Medicine, Perth Children's Hospital, Nedlands, Western Australia, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Azithromycin improves symptomology in various chronic airway diseases exacerbated by viral infections. However, the mechanisms underlying the apparent antiviral effects of azithromycin remain unclear.Methods: Airway epithelial cells (AECs) from healthy children were cultured, expanded and differentiated into air-liquid interface (ALI) cultures. Submerged and differentiated primary cultures were treated with 10 µM of AZM for 24h and subsequently infected with human rhinovirus (HRV)-1b for 24h. Virus receptor expression, replication, progeny release and inflammatory cytokines (IL-1β, - 6, -8 and IP-10) were then measured. Barrier integrity was determined via qPCR, in-cell western (ICW), immunofluorescence confocal microscopy, transepithelial electrical resistance (RT) measurement and an apparent permeability (Papp) assay.Results: Treatment with AZM for 24h at the concentrations of 0.1, 1 and 10 µM did not have any significant impact on either cellular viability or cytotoxicity in un-infected cells. No significant effect on viral receptor, cytokine expression was observed in non-infected cells treated with 10 µM AZM. Similarly, there was no significant change in both occludin and ZO-1 expression in non-infected cells. However, claudin-1 gene expression was significantly reduced but corresponding protein expression was significantly increased following 10 µM AZM. Although RT was significantly lower, this was not corroborated by any significant change in epithelial permeability after 10 µM AZM treatment. Subsequent to HRV-1b infection, 10 µM AZM treatment significantly reduced cytotoxicity induced by infection. Viral receptor expression were not affected with AZM pre-treatment but a significant decrease in viral replication was observed. Except for IP-10, expression of IL-1β, -6, and -8 was significantly reduced. Gene and protein expression of key epithelial junctions were significantly higher in treated, infected cells, which were concomitant with epithelial barrier function.Discussions: This study identified that AZM can protect against HRV-1b-induced epithelial damage. Our data, demonstrating the antiviral, anti-inflammatory, and barrier-protective effects in vitro are strongly indicative of pleiotropic mechanisms of AZM for mitigating viral infection and its consequences. These effects are likely to contribute to the benefits observed in clinical trials of AZM in a number of chronic respiratory diseases.
Keywords: Airway epithelium, tight junction, human rhinovirus, Azithromycin, Barrier function
Received: 22 Nov 2024; Accepted: 28 May 2025.
Copyright: © 2025 Looi, Sutanto, Iosifidis, Berry, Kicic and Stick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kevin Looi, Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Perth, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.